tetano
Editor, Senior Moderator
Nat Microbiol
. 2022 Jun 15.
doi: 10.1038/s41564-022-01170-4. Online ahead of print.
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
Ryuta Uraki[SUP] #[/SUP][SUP] 1 2 [/SUP], Maki Kiso[SUP] #[/SUP][SUP] 1 [/SUP], Masaki Imai[SUP] #[/SUP][SUP] 1 2 [/SUP], Seiya Yamayoshi[SUP] 1 2 [/SUP], Mutsumi Ito[SUP] 1 [/SUP], Seiichiro Fujisaki[SUP] 3 [/SUP], Emi Takashita[SUP] 3 [/SUP], Michiko Ujie[SUP] 1 2 [/SUP], Yuri Furusawa[SUP] 1 2 [/SUP], Atsuhiro Yasuhara[SUP] 1 [/SUP], Kiyoko Iwatsuki-Horimoto[SUP] 1 [/SUP], Yuko Sakai-Tagawa[SUP] 1 [/SUP], Shinji Watanabe[SUP] 3 [/SUP], Hideki Hasegawa[SUP] 3 [/SUP], Yoshihiro Kawaoka[SUP] 4 5 6 [/SUP]
Affiliations
Abstract
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants.
. 2022 Jun 15.
doi: 10.1038/s41564-022-01170-4. Online ahead of print.
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
Ryuta Uraki[SUP] #[/SUP][SUP] 1 2 [/SUP], Maki Kiso[SUP] #[/SUP][SUP] 1 [/SUP], Masaki Imai[SUP] #[/SUP][SUP] 1 2 [/SUP], Seiya Yamayoshi[SUP] 1 2 [/SUP], Mutsumi Ito[SUP] 1 [/SUP], Seiichiro Fujisaki[SUP] 3 [/SUP], Emi Takashita[SUP] 3 [/SUP], Michiko Ujie[SUP] 1 2 [/SUP], Yuri Furusawa[SUP] 1 2 [/SUP], Atsuhiro Yasuhara[SUP] 1 [/SUP], Kiyoko Iwatsuki-Horimoto[SUP] 1 [/SUP], Yuko Sakai-Tagawa[SUP] 1 [/SUP], Shinji Watanabe[SUP] 3 [/SUP], Hideki Hasegawa[SUP] 3 [/SUP], Yoshihiro Kawaoka[SUP] 4 5 6 [/SUP]
Affiliations
- PMID: 35705860
- DOI: 10.1038/s41564-022-01170-4
Abstract
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants.